Literature DB >> 11970913

Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease.

Richard E K Russell1, Sarah V Culpitt, Carmen DeMatos, Louise Donnelly, Michael Smith, John Wiggins, Peter J Barnes.   

Abstract

Destruction of lung elastin is critical for development of emphysema associated with chronic obstructive pulmonary disease (COPD). Lung macrophages release elastolytic enzymes, including matrix metalloproteinase (MMP)-9, along with tissue inhibitors of MMP (TIMP). We examined the production and activity of macrophage-derived MMP-9 and TIMP-1 from alveolar macrophages (AM) from smokers with COPD, healthy smokers (HS), and nonsmokers (NS). AM were stimulated with either lipopolysaccharide (LPS), interleukin (IL)-1 beta, or cigarette smoke-conditioned culture medium (CSM). AM from patients with COPD released greater amounts of MMP-9 with greater enzymatic activity than HS and NS. In contrast, AM from NS released more TIMP-1 than cells from HS and subjects with COPD. LPS and IL-1 beta caused a dose-dependent increase in MMP-9 release and activity, together with increased levels of TIMP-1. Dexamethasone prevented the increase in MMP-9 release, and increased TIMP-1 release. CSM increased MMP-9 and TIMP-1 release from AM of all groups. Dexamethasone decreased CSM-stimulated MMP-9 release, but had no effect on MMP-9 activity This study suggests that macrophages might be important in the development of COPD because these cells exhibit increased levels of elastolytic activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11970913     DOI: 10.1165/ajrcmb.26.5.4685

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  112 in total

1.  Emphysema mediated by lung overexpression of ADAM10.

Authors:  Hiroki Saitoh; Philip L Leopold; Ben-Gary Harvey; Timothy P O'Connor; Stefan Worgall; Neil R Hackett; Ronald G Crystal
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

Review 2.  Pathogenesis of chronic obstructive pulmonary disease.

Authors:  William MacNee
Journal:  Proc Am Thorac Soc       Date:  2005

Review 3.  Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease.

Authors:  Caroline A Owen
Journal:  Proc Am Thorac Soc       Date:  2005

4.  Gram-positive and Gram-negative bacteria synergize with oxidants to release CXCL8 from innate immune cells.

Authors:  Mark J Paul-Clark; Rosalinda Sorrentino; Lucy K Bailey; Shiranee Sriskandan; Jane A Mitchell
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

Review 5.  Chronic obstructive pulmonary disease * 12: New treatments for COPD.

Authors:  P J Barnes
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

Review 6.  Matrix metalloproteinases in emphysema.

Authors:  Sina A Gharib; Anne M Manicone; William C Parks
Journal:  Matrix Biol       Date:  2018-03-23       Impact factor: 11.583

Review 7.  Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?

Authors:  S F Paul Man; Don D Sin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Myeloid-specific Fos-related antigen-1 regulates cigarette smoke-induced lung inflammation, not emphysema, in mice.

Authors:  Michelle Vaz; Subbiah Rajasekaran; Haranatha R Potteti; Sekhar P Reddy
Journal:  Am J Respir Cell Mol Biol       Date:  2015-07       Impact factor: 6.914

Review 9.  Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes.

Authors:  John A Hansen; Effie W Petersdorf; Ming-Tseh Lin; Steven Wang; Jason W Chien; Barry Storer; Paul J Martin
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

10.  Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract.

Authors:  Sang Eun Kim; Tran Thi Thanh Thuy; Ji Hyun Lee; Jai Youl Ro; Young An Bae; Yoon Kong; Jee Yin Ahn; Dong Soon Lee; Yeon Mock Oh; Sang Do Lee; Yun Song Lee
Journal:  Exp Mol Med       Date:  2009-04-30       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.